Atlas Trials

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Clinical trial NCT03428217 · COMPLETED

Trial details

NCT number
NCT03428217
Sponsor
Calithera Biosciences, Inc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Start date
2018-04-24
Primary completion
2020-08-31
Enrollment
444

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.